Wishing you all the joys of the season! 
Vaccine Adjuvant Market Size and Forecast (2020-2030)
Vaccine Adjuvant Market Size and Forecast (2020 – 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others), Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
$3,633 – $6,433
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
An adjuvant is a component added to vaccine preparations to create a stronger immune response in people receiving the vaccine. The rising occurrence of infectious disease outbreaks and pandemics and regulatory approvals of veterinary vaccine adjuvants are the key factors propelling the market development. However, product recall and adverse effects hamper the vaccine adjuvant market growth.
Growth Drivers:
Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches Creates Opportunities for Vaccine Adjuvant Market
The National Institute of Allergy and Infectious Disease (NIAID) plays an important role in developing, discovering, and characterizing new vaccine adjuvants. The institute plays a crucial role in improving the efficacy of current vaccines, designing new or better vaccines against existing and emerging infectious diseases, and developing vaccines to treat allergies, autoimmune diseases, and cancer. Additionally, NIAID’s vaccine adjuvant research program aims to develop a set of adjuvants, including candidates that can be matched with antigens to optimize the final vaccine efficacy. Therefore, to foster the collaboration between NIAID-supported vaccine adjuvant researchers and a broader scientific community, NIAID established the Vaccine Adjuvant Compendium (VAC) in 2020. This web-based tool displays adjuvant characteristics to help vaccine developers identify adjuvants suitable for their target disease.
Companies in the vaccine business, such as SK Biosciences and GSK, are producing adjuvants on a large scale to meet global demand by implementing growth strategies such as collaborations. For instance, in April 2022, SK Biosciences and GSK announced the submission of a biological license application for SKYCovione to the Korean Ministry of Food and Drug Safety (KMFDS) following positive data obtained in Phase 3 clinical trials. Therefore, the support provided by various government authorities to foster vaccine adjuvant research and development, collaborations between top manufacturers, and innovative product launches through such collaborative business strategies are likely to provide lucrative opportunities for the growth of the vaccine adjuvants market during the forecast period.
The mineral salt adjuvant segment held the largest share of the vaccine adjuvant market by adjuvant class 2022. The market for the emulsion adjuvant segment is anticipated to grow at the fastest CAGR of 14.6% during the forecast period. Mineral salts such as insoluble aluminum salts and calcium phosphates are used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants help induce early and long-lasting protective immunity. Aluminum adjuvants indicated for use in human vaccines are regulated by the US Food and Drug Administration (FDA), and small amounts of aluminum are added to help the body build higher immunogenicity than the antigen alone in the vaccine. Mineral salt adjuvant formulation at the inflammatory site produces a fast immune response by releasing pro-inflammatory cytokines. Therefore, the ability of mineral salt-based adjuvants to induce a fast immune response toward antigens favors the vaccine adjuvants market growth.
In 2022, North America contributed the largest global vaccine adjuvant market share. Asia Pacific is expected to register the highest CAGR during 2022–2030. Accelerated product approvals for vaccine adjuvants bolster market growth in North America. Additionally, the presence of top manufacturers producing adjuvants further enhances the overall market growth.
Fast product approval processes benefit the vaccine adjuvants market in the US. In May 2023, GlaxoSmithKline (GSK) won US Food and Drug Administration (FDA) approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) vaccine intended for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Thus, Arexvy became the world’s first FDA-approved RSV vaccine for older adults. In October 2022, Novavax, Inc. received an Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, indicated as a booster for adult patients.
Industry Developments and Future Opportunities:
Various strategic developments by leading players operating in the vaccine adjuvant market are listed below:
• In April 2022, GSK plc and SK Bioscience submitted a biologics license application for SKYCovione, a recombinant protein-based, adjuvanted COVID-19 vaccine candidate. It contains GSK’s pandemic adjuvant. The companies have submitted a biologics license application to the Korean Ministry of Food and Drug Safety following the positive data obtained in Phase III clinical trials.
• In November 2021, Seppic launched MONTANIDE GEL P PR, an aqueous adjuvant based on a polymeric technology exclusively dedicated to avian injectable vaccines, meeting the need for innocuity in the avian market. In addition, MONTANIDE GEL P PR is particularly stable and can resist destabilizing antigenic media frequently used in avian vaccines.
• In October 2023, SPI Pharma Inc. and Q-Vant Biosciences Inc. announced a partnership that combines Q-Vant’s leadership in sustainable saponin extraction technology with SPI’s global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in expanding Q-Vant’s proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.
• In January 2023, the Korean Ministry of Food and Drug Safety (KMFDS) granted SK Bioscience enhanced manufacturing and marketing authorization for NuvaxovidTM to be administered to adults aged 18 and above as a booster.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
Market Trend
Technological Advancements
Currently, in the US, aluminum salt or gel-based adjuvants are used predominantly in licensed vaccines. Monophosphoryl lipid A (MPL) adjuvant and hydrophobic copolymers are some examples of these components. Hydrophobic microspheres pose challenges during vaccine production. The problems include a lot of environmental waste disposal and contamination issues, and it is also time-consuming, costly, and inefficient. Therefore, manufacturers are emphasizing developing novel technologies to avoid using organic solvents. For example, Aphios’ Vaccine Adjuvant Technology encompasses nanotechnology, and its production includes the use of supercritical, critical, or near-critical fluids with or without polar cosolvents such as ethanol [referred to as superfluids (SFS)]. Biodegradable biopolymers are dissolved in SFS and mixed with subunit vaccines in an aqueous solution or as a slurry of nanoparticles. Therefore, such new vaccine adjuvant technologies are being developed for making biodegradable polymer nanospheres (PNS) through novel processes, which allows vaccine manufacturers to rule out the use of organic solvents. Thus, technological advancements are likely to bring new trends in the vaccine adjuvants market in the coming years.
Approvals of Veterinary Vaccine Adjuvants
Vaccinating animals against common diseases remains the most successful method worldwide to prevent financial and other losses from infectious diseases in animal farming. The number of regulatory approvals for adjuvants for veterinary vaccines is increasing with the growing focus among manufacturers on developing vaccines with greater efficacy and stability. Montanide is one of the known veterinary vaccine adjuvants. The Montanide adjuvant range is based on three core technologies—emulsions, micro-emulsions, and polymers.
Below is a list of approved veterinary vaccine adjuvants in India from January 2020 to September 2022.
Veterinary Vaccines Adjuvants for Veterinary Infections
Company Name Product Disease Indication
Boehringer Ingelheim Inactivated Vaccine in Oil Adjuvant Newcastle Disease, Disease Bronchitis, Infectious Bursal Disease, and Avial Viral Arthritis
Virbac Animal Health Pvt. Ltd. Inactivated Vaccine in Oil Adjuvant Newcastle Disease and Ranikhet Disease
Virbac Animal Health Pvt. Ltd. Inactivated Vaccine in Oil Adjuvant Newcastle Disease, Ranikhet Disease, Avian infectious Bronchitis, and Combined Newcastle Disease
Source: CDSCO
Therefore, an upsurge in adjuvant approvals for veterinary vaccines accelerates the overall market growth of vaccine adjuvants.
Adjuvant Class-Based Insights
By adjuvant class, the vaccine adjuvants market is segmented as mineral salt-based adjuvants, emulsion adjuvants, liposome adjuvants, and others. The mineral salt-based adjuvants segment held a larger market share in 2022 and is anticipated to register the highest CAGR during the forecast period. Mineral salts such as insoluble aluminum salts and calcium phosphates are used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants help induce early and long-lasting protective immunity. Aluminum adjuvants indicated for use in human vaccines are regulated by the US Food and Drug Administration (FDA), and small amounts of aluminum are added to help the body build higher immunogenicity than the antigen alone in the vaccine. Mineral salt adjuvants formulation at inflammatory site produces fast immune response by release of pro-inflammatory cytokines. Therefore, the ability of mineral salt-based adjuvants to induce a fast immune response toward antigens favors the vaccine adjuvants market growth.
SPI Pharma Inc, GSK Plc, CSL Ltd, Seppic SA, Hawaii Biotech Inc, Dynavax Technologies Corp, InvivoGen SAS, Croda International Plc, Novavax Inc., and Phibro Animal Health Corp are among the key companies operating in the vaccine adjuvants market. Leading players adopt strategies such as launching new products, expanding and diversifying their market presence, and expanding new customer base to tap prevailing business opportunities.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the vaccine adjuvants market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the global vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Vaccine Adjuvants Market Landscape
4.1 PEST Analysis
5. Vaccine Adjuvants Market – Key Market Dynamics
5.1 Vaccine Adjuvants Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
5.2.2 Approvals of Veterinary Vaccine Adjuvants
5.3 Market Restraints
5.3.1 Product Recalls and Adverse Effects
5.4 Market Opportunity
5.4.1 Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches
5.5 Future Trends
5.5.1 Technological Advancements
5.6 Impact of Drivers and Restraints:
6. Vaccine Adjuvants Market – Global Market Analysis
6.1 Vaccine Adjuvants Market Revenue (US$ Million), 2022–2030
6.1.1 Overview
6.2 Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. Vaccine Adjuvants Market Analysis – by Adjuvant Class
7.1 Overview
7.2 Mineral Salt Adjuvant
7.2.1 Overview
7.2.2 Mineral Salt Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Emulsion Adjuvant
7.3.1 Overview
7.3.2 Emulsion Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Liposome Adjuvant
7.4.1 Overview
7.4.2 Liposome Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Vaccine Adjuvants Market Analysis – by Type
8.1 Human Vaccine Adjuvant
8.1.1 Overview
8.1.2 Human Vaccine Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Veterinary Vaccine Adjuvant
8.2.1 Overview
8.2.2 Veterinary Vaccine Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9. Vaccine Adjuvants Market – Geographical Analysis
9.1 North America
9.1.1 North America Vaccine Adjuvants Market Overview
9.1.2 North America: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.2.1 North America: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Adjuvant Class
9.1.2.2 North America: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
9.1.3 North America: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
9.1.3.1 United States: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3.1.1 Overview
9.1.3.1.2 United States: Glucose Monitoring Devices Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3.1.3 United States: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.1.3.1.4 United States: Vaccine Adjuvants Market Breakdown, by Type
9.1.3.2 Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3.2.1 Overview
9.1.3.2.2 Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3.2.3 Canada: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.1.3.2.4 Canada: Vaccine Adjuvants Market Breakdown, by Type
9.1.3.3 Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3.3.1 Overview
9.1.3.3.2 Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3.3.3 Mexico: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.1.3.3.4 Mexico: Vaccine Adjuvants Market Breakdown, by Type
9.2 Europe
9.2.1 Europe Vaccine Adjuvants Market Overview
9.2.2 Europe: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
9.2.2.1 Europe: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Adjuvant Class
9.2.2.2 Europe: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
9.2.3 Europe: Vaccine Adjuvants Market
9.2.3.1 Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.1.1 Overview
9.2.3.1.2 Germany: Glucose Monitoring Devices Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.2.3.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
9.2.3.2 United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.2.1 Overview
9.2.3.2.2 United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.2.3.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
9.2.3.3 France: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.3.1 Overview
9.2.3.3.2 France: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.2.3.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
9.2.3.4 Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.4.1 Overview
9.2.3.4.2 Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.2.3.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
9.2.3.5 Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.5.1 Overview
9.2.3.5.2 Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.2.3.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
9.2.3.6 Rest of Europe: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.6.1 Overview
9.2.3.6.2 Rest of Europe: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3.6.3 Rest of Europe: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.2.3.6.4 Rest of Europe: Vaccine Adjuvants Market Breakdown, by Type
9.3 Asia Pacific
9.3.1 Asia Pacific Vaccine Adjuvants Market Overview
9.3.2 Asia Pacific: Vaccine Adjuvants Market
9.3.2.1 Asia Pacific: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Adjuvant Class
9.3.3 Asia Pacific: Vaccine Adjuvants Market
9.3.3.1 Asia Pacific: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
9.3.4 Asia Pacific: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
9.3.4.1 China: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.1.1 Overview
9.3.4.1.2 China: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.1.3 China: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.3.4.1.4 China: Vaccine Adjuvants Market Breakdown, by Type
9.3.4.2 Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.2.1 Overview
9.3.4.2.2 Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.2.3 Japan: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.3.4.2.4 Japan: Vaccine Adjuvants Market Breakdown, by Type
9.3.4.3 India: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.3.1 Overview
9.3.4.3.2 India: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.3.3 India: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.3.4.3.4 India: Vaccine Adjuvants Market Breakdown, by Type
9.3.4.4 Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.4.1 Overview
9.3.4.4.2 Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.4.3 Australia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.3.4.4.4 Australia: Vaccine Adjuvants Market Breakdown, by Type
9.3.4.5 South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.5.1 Overview
9.3.4.5.2 South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.5.3 South Korea: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.3.4.5.4 South Korea: Vaccine Adjuvants Market Breakdown, by Type
9.3.4.6 Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.6.1 Overview
9.3.4.6.2 Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4.6.3 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.3.4.6.4 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Type
9.4 Middle East and Africa
9.4.1 Middle East and Africa Vaccine Adjuvants Market Overview
9.4.2 Middle East and Africa: Vaccine Adjuvants Market
9.4.2.1 Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Adjuvant Class
9.4.2.2 Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
9.4.3 Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
9.4.3.1 Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3.1.1 Overview
9.4.3.1.2 Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3.1.3 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.4.3.1.4 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Type
9.4.3.2 South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3.2.1 Overview
9.4.3.2.2 South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3.2.3 South Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.4.3.2.4 South Africa: Vaccine Adjuvants Market Breakdown, by Type
9.4.3.3 United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3.3.1 Overview
9.4.3.3.2 United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3.3.3 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.4.3.3.4 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Type
9.4.3.4 Rest of Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3.4.1 Overview
9.4.3.4.2 Rest of Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3.4.3 Rest of Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.4.3.4.4 Rest of Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Type
9.5 South and Central America
9.5.1 South and Central America Vaccine Adjuvants Market Overview
9.5.2 South and Central America: Vaccine Adjuvants Market
9.5.2.1 South and Central America: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Adjuvant Class
9.5.3 South and Central America: Vaccine Adjuvants Market
9.5.3.1 South and Central America: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
9.5.4 South and Central America: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
9.5.4.1 Brazil: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.5.4.1.1 Overview
9.5.4.1.2 Brazil: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.5.4.1.3 Brazil: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.5.4.1.4 Brazil: Vaccine Adjuvants Market Breakdown, by Type
9.5.4.2 Argentina: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.5.4.2.1 Overview
9.5.4.2.2 Argentina: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.5.4.2.3 Argentina: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.5.4.2.4 Argentina: Vaccine Adjuvants Market Breakdown, by Type
9.5.4.3 Rest of South and Central America: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.5.4.3.1 Overview
9.5.4.3.2 Rest of South and Central America: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.5.4.3.3 Rest of South and Central America: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
9.5.4.3.4 Rest of South and Central America: Vaccine Adjuvants Market Breakdown, by Type
10. Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Global Vaccine Adjuvants Market
10.3 Organic Developments
10.3.1 Overview
10.4 Inorganic Developments
10.4.1 Overview
11. Company Profiles
11.1 SPI Pharma Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 GSK Plc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 THREATS
11.2.7 Key Developments
11.3 CSL Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Seppic SA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Hawaii Biotech Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Dynavax Technologies Corp
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 InvivoGen SAS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Croda International Plc
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Novavax Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Phibro Animal Health Corp
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.1 Glossary of Terms
LIST OF TABLES
Table 1. Vaccine Adjuvants Market Segmentation
Table 2. North America: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 3. North America: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 4. United States: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 5. United States: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 6. Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 7. Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 8. Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 9. Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 10. Europe: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 11. Europe: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 12. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 13. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 14. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 15. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 16. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 17. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 18. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 19. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 20. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 21. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 22. Rest of Europe: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 23. Rest of Europe: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 24. Asia Pacific: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 25. Asia Pacific: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 26. China: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 27. China: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 28. Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 29. Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 30. India: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 31. India: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 32. Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 33. Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 34. South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 35. South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 36. Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 37. Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 38. Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 39. Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 40. Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 41. Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 42. South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 43. South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 44. United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 45. United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 46. Rest of Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 47. Rest of Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 48. South and Central America: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 49. South and Central America: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 50. Brazil: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 51. Brazil: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 52. Argentina: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 53. Argentina: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 54. Rest of South and Central America: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 55. Rest of South and Central America: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 56. Organic Developments Done by Companies
Table 57. Inorganic Developments Done by Companies
Table 58. Glossary of Terms, Vaccine Adjuvants Market
LIST OF FIGURES
Figure 1. Vaccine Adjuvants Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Vaccine Adjuvants Market Revenue (US$ Million), 2022–2030
Figure 5. Vaccines Adjuvants Market, By Geography Forecast Analysis, 2022 & 2030
Figure 6. Vaccine Adjuvants Market Share (%) – by Adjuvant Class (2022 and 2030)
Figure 7. Mineral Salt Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Emulsion Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Liposome Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 12. Human Vaccine Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Veterinary Vaccine Adjuvant: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America: Vaccine Adjuvants Market by Key Countries – Revenue (2022) US$ Million
Figure 15. North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 17. United States: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 18. Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 19. Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 20. Europe: Vaccine Adjuvants Market – Revenue by Key Countries Revenue 2022 (US$ Million)
Figure 21. Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Europe: Vaccine Adjuvants Market (2022 and 2030)
Figure 23. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 24. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 25. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 26. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 27. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 28. Rest of Europe: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 29. Asia Pacific: Vaccine Adjuvants Market – Revenue by Key Countries 2022 (US$ Million)
Figure 30. Asia Pacific: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Asia Pacific: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 32. China: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 33. Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 34. India: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 35. Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 36. South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 37. Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 38. Middle East and Africa: Vaccine Adjuvants Market by Key Countries – Revenue 2022 (US$ Million)
Figure 39. Middle East and Africa: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
Figure 40. Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 41. Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 42. South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 43. United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 44. Rest of Middle East and Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 45. South and Central America: Vaccine Adjuvants Market by Key Countries – Revenue 2022 (US$ Million)
Figure 46. South and Central America: Vaccine Adjuvants Market, Revenue and Forecast to 2030 (US$ Million)
Figure 47. South and Central America: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 48. Brazil: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 49. Argentina: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 50. Rest of South and Central America: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 51. Growth Strategies in the Global Vaccine Adjuvants Market
The List of Companies – Vaccine Adjuvant Market
o SPI Pharma Inc
o GSK Plc
o CSL Ltd
o Seppic SA
o Hawaii Biotech Inc
o Dynavax Technologies Corp
o InvivoGen SAS
o Croda International Plc
o Novavax Inc
o Phibro Animal Health Corp
You must be logged in to post a review.
Reviews
There are no reviews yet.